Literature DB >> 15592710

[Early instillation in superficial bladder carcinoma. Current status].

S Langbein1, A Häcker, J K Badawi, M S Michel, P Alken.   

Abstract

The high recurrence rate in superficial bladder cancer (>70%) is caused by the adhesion of free floating tumor cells during transurethral treatment, by incomplete resections, and by overlooked and new tumors. Frequent follow-ups and reoperations are necessary. A single immediate instillation after TUR shows positive effects in reducing recurrence rates and is therefore recommended in the European Guidelines from 2001. The amount, concentration, instillation time, and substances have not yet been standardized. By analyzing the literature we found many different techniques of early instillation therapy. Different substances, concentrations, varying instillation times, and application times make a comparison of these studies very difficult. Further studies are needed to standardize early postoperative instillation therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592710     DOI: 10.1007/s00120-004-0720-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  17 in total

1.  Papillomata of bladder treated with podophyllin; preliminary report.

Authors:  J E SEMPLE
Journal:  Br Med J       Date:  1948-06-26

2.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.

Authors:  J L Au; R A Badalament; M G Wientjes; D C Young; J A Warner; P L Venema; D L Pollifrone; J D Harbrecht; J L Chin; S P Lerner; B J Miles
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

3.  The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.

Authors:  D W Newling; J Hetherington; S K Sundaram; M R Robinson; L Kisbenedek
Journal:  Eur Urol       Date:  2001-06       Impact factor: 20.096

4.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.

Authors:  C Bouffioux; K H Kurth; A Bono; W Oosterlinck; C B Kruger; M De Pauw; R Sylvester
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

5.  Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.

Authors:  P Rajala; T Liukkonen; M Raitanen; E Rintala; E Kaasinen; M Helle; O Lukkarinen
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

6.  Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.

Authors:  K G Burnand; P J Boyd; M E Mayo; K E Shuttleworth; R W Lloyd-Davies
Journal:  Br J Urol       Date:  1976-02

7.  The mechanism of human bladder tumor implantation in an in vitro model.

Authors:  D Pode; Y Alon; A T Horowitz; I Vlodavsky; S Biran
Journal:  J Urol       Date:  1986-08       Impact factor: 7.450

8.  Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin.

Authors:  R J Popert; J Goodall; M J Coptcoat; P M Thompson; M K Parmar; J R Masters
Journal:  Br J Urol       Date:  1994-08

9.  Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors.

Authors:  F Calais da Silva; L Denis; A Bono; C Bollack; C Bouffioux
Journal:  Eur Urol       Date:  1988       Impact factor: 20.096

10.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; Adrian P M van der Meijden
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.